# Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

> **NCT00550004** · PHASE2 · TERMINATED · sponsor: **SciClone Pharmaceuticals** · enrollment: 153 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** RP101
- **DRUG:** Gemcitabine (1000 mg/m2)

## Key facts

- **NCT ID:** NCT00550004
- **Lead sponsor:** SciClone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09
- **Primary completion:** 2009-08
- **Final completion:** 2009-10
- **Target enrollment:** 153 (ESTIMATED)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00550004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00550004, "Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00550004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*